Latest Breaking News On - Australasian leukaemia - Page 3 : comparemela.com

Mendus And Australasian Leukaemia & Lymphoma Group To Expand Clinical Testing Of Vididencel As Maintenance Treatment For AML

Mendus And Australasian Leukaemia & Lymphoma Group To Expand Clinical Testing Of Vididencel As Maintenance Treatment For AML
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesErik mantingAndrew weiAustralasian leukaemia lymphoma groupPeter maccallum cancer centreNasdaq pressAmerican society of hematology conferenceAmerican society of hematologyAustralasian leukaemiaLymphoma groupJeroen roversChief medical officerProfessor dr andrew weiAcute myeloid leukemiaRoyal melbourne hospitalAmerican society

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

First clinical trial to explore the potential of imetelstat in relapsed/refractory acute myeloid leukemia and higher risk myelodysplastic syndromes Data from animal pre-clinical models. | June 13, 2023

Uwe platzbeckerFaye fellerDepartment of hematologyDrug administrationEuropean myelodysplastic neoplasms cooperative groupGeron corporation nasdaqAustralasian leukaemia lymphoma groupLeipzig university hospitalGeron corporationExecutive vice presidentChief medical officerCellular therapyPrincipal investigatorEuropean leukemianetAustralasian leukaemiaLymphoma group

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) Q1 2023 Earnings Call Transcript

Operator: Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call. Today s call is being recorded.

United statesAnjali ganguliEva priviteraKalpit patelBrad caninoNeil gallagherSharon klahreAnupam ramaMadhu kumarMichael metzgerPeter lawsonDara azarIncyte jakafiKeith goldanSanofi rezurockYigal nochomovitz

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,.

United statesSharon klahreMichaela metzgerCompany on twitterSyndax pharmaceuticalsExchange commissionAmerican society of hematologyInternational numberLymphoma groupPrnewswire syndax pharmaceuticals incSyndax pharmaceuticals incLeukemia lymphoma society beatChief executiveAmerican societyAnnual meetingNew drug application

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,.

United statesSharon klahreMichaela metzgerSyndax pharmaceuticalsDrug administrationLeukemia lymphoma societyExchange commissionAmerican society of hematologyInternational numberLymphoma groupPrnewswire syndax pharmaceuticals incSyndax pharmaceuticals incAmerican societyAnnual meetingChief executiveNew drug application